Form 4 for PYXS Pyxis Oncology, Inc.
Accepted 2023-09-08 00:00:00 ET · period of report 2023-09-07 · accession 0001209191-23-048814 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-08 | 2023-09-07 | PYXS | Sullivan Lara | Pres, CEO, Dir | A - Grant | $0.00 | +469.5K | 2.63M | +22% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-07 | A | A | 469,483 | $0.00 | 2,625,182 | D | — | — | (F1) Represents restricted stock units that are fully vested. |